Toxicogenomics – A Drug Development Perspective - Genomic Biomarkers for Pharmaceutical Development - page 144

[20] Raghavan N, et al. A linear prediction rule based on ensemble classiiers for non-genotoxic carcinogenicity.
Statist Biopharm Res 2012;4(2):185-93.
[21] Rusyn I, et al. Predictive modeling of chemical hazard by integrating numerical descriptors of chemical struc-
tures and short-term toxicity assay data. Toxicol Sci 2012;127(1):1-9.
[22] Doktorova TY, et al. Comparison of genotoxicant-modiied transcriptomic responses in conventional and epi-
genetically stabilized primary rat hepatocytes with in vivo rat liver data. Arch Toxicol 2012;86(11):1703-15.
[23] Jetten MJA, et al. Omics analysis of low dose acetaminophen intake demonstrates novel response pathways
in humans. Toxicol Appl Pharmacol 2012;259(3):320-8.
[24] Liao MY, Liu HG. Gene expression proiling of nephrotoxicity from copper nanoparticles in rats after
repeated oral administration. Environ Toxicol Pharmacol 2012;34(1):67-80.
[25] Faqi A. A comprehensive guide to toxicology in preclinical drug development. London: Elsevier; 2013.
[26] Hwang MS, et al. Application of toxicogenomic technology for the improvement of risk assessment. Mol Cell
Toxicol 2008;4(3):260-6.
[27] Wills Q. SimuGen Ltd: reliable, early prediction of drug toxicity with toxicogenomics, human cell culture and
computational models. Pharmacogenomics 2007;8(8):1081-4.
[28] Amir-Aslani A. Toxicogenomic predictive modeling: emerging opportunities for more eficient drug discov-
ery and development. Technol Forecast Soc Change 2008;75(7):905-32.
[29] Suter L, et al. EU Framework 6 Project: predictive toxicology (PredTox) - overview and outcome. Toxicol
Appl Pharmacol 2011;252(2):73-84.
[30] Thomas CE, Will Y. The impact of assay technology as applied to safety assessment in reducing compound
attrition in drug discovery. Expert Opin Drug Discov 2012;7(2):109-22.
[31] Poma A, Di Giorgio ML. Toxicogenomics to improve comprehension of the mechanisms underlying
responses of in vitro and in vivo systems to nanomaterials: a review. Curr Genomics 2008;9(8):571-85.
[32] Aardema MJ, MacGregor JT. Toxicology and genetic toxicology in the new era of 'toxicogenomics': impact of
'-omics' technologies. Mutat Res Fund Mol Mech Mutagen 2002;499(1):13-25.
[33] Chen MJ, Zhang M, Borlak J, Tong W, A decade of toxicogenomic research and its contribution to toxicologi-
cal science. Toxicol Sci 2012;130(2):217-28.
[34] Beger RD, Colatsky T. Metabolomics data and the biomarker qualiication process. Metabolomics 2012;8(1):2-7.
[35] Delles C, Neisius U, Carty DM. Proteomics in hypertension and other cardiovascular diseases. Ann Med
2012;44:S55-64.
[36] Schrattenholz A, et al. Protein biomarkers for in vitro testing of toxicology. Mutat Res Genetic Toxicol Environ
Mutagen 2012;746(2):113-23.
[37] Quackenbush J. Microarrays - guilt by association. Science 2003;302(5643):240-1.
[38] Lujambio A, Lowe SW. The microcosmos of cancer. Nature 2012;482(7385):347-55.
[39] Lindow M, Kauppinen S. Discovering the irst microRNA-targeted drug. J Cell Biol 2012;199(3):407-12.
[40] Mendrick DL. Transcriptional proiling to identify biomarkers of disease and drug response.
Pharmacogenomics 2011;12(2):235-49.
[41] Chen BS, Li CW. Analyzing microarray data in drug discovery using systems biology. Expert Opin Drug
Discov 2007;2(5):755-68.
[42] Ma HC, Horiuchi KY. Chemical microarray: a new tool for drug screening and discovery. Drug Discov Today
2006;11(13-14):661-8.
[43] Petersen D, et al. Three microarray platforms: an analysis of their concordance in proiling gene expression.
BMC Genomics 2005;6(1):63.
[44] Hardiman G. Microarray platforms - comparisons and contrasts. Future Med 2004;5(5):487-502.
[45] Ju W, et al. Identiication of genes with differential expression in chemoresistant epithelial ovarian cancer
using high-density oligonucleotide microarrays. Oncol Res 2009;18(2-3):47-56.
[46] Zidek N, et al. Acute hepatotoxicity: a predictive model based on focused Illumina microarrays. Toxicol Sci
2007;99(1):289-302.
[47] Schulze A, Downward J. Navigating gene expression using microarrays - a technology review. Nat Cell Biol
2001;3(8):E190-5.
[48] Edwards HD, Nagappayya SK, Pohl NLB. Probing the limitations of the luorous content for tag-mediated
microarray formation. Chem Commun 2012;48(4):510-12.
[49] Khouja MH, et al. Limitations of tissue microarrays compared with whole tissue sections in survival analysis.
Oncol Lett 2010;1(5):827-31.